BRIDGEWATER, N.J.--(BUSINESS WIRE)--Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) announced today that on November 14, 2006 the Securities and Exchange Commission declared effective Enzon’s Form S-3 registration statement covering the resale by selling holders named therein of up to an aggregate principal amount of $275,000,000 of Enzon’s 4% Convertible Senior Notes due 2013 (the “Notes”) and the shares of common stock issuable upon the conversion of the Notes.
